KLK11
Basics
Aliases:
This biomarker is also known as:- hk11,
- TLSP,
- Serine protease 20,
- kallikrein 11,
- kallikrein-related peptidase 11,
- Hippostasin,
- PRSS20,
- Kallikrein-11,
Description…
The glandular kallikreins are a distinct group of serine proteases with molecular masses of 25,000 to 40,000. Kallikreins are a subgroup of serine proteases having diverse physiological functions. hk11 is a possible multifunctional protease which efficiently cleaves 'bz-Phe-Arg-4-methylcoumaryl-7-amide', a kallikrein substrate, and weakly cleaves other substrates for kallikrein and trypsin. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Several human kallikrein genes have been isolated. Expressed in brain, skin and prostate. Isoform 1 is expressed preferentially in brain. Isoform 2 is expressed in prostate.
Attributes
| QA State: | Accepted |
|---|---|
| Type: | Protein |
| Short Name: |
Organs
The following organs have data associated with this biomarker…
Prostate
Attributes
| Phase: | Two |
|---|---|
| QA State: | Accepted |
Overview
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene, hk11 (KLK11) is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Alternate splicing of this gene results in multiple transcript variants encoding distinct isoforms which are differentially expressed.
Performance Comment
hK2, hK4 and hK11 do not distinguish cases from controls in these populations.
Supporting Study Data
The following studies/protocols provide evidence supporting KLK11 indications for the Prostate…
Prostate Rapid Pre-Validation Set
Determine which markers move to validation using the prospectie prostate reference set samples.
View more about this studyBiomarker Characteristics Summary
No statistics found.
Decision Rule
No clinically useful decision rule found.
Additional Study-Specific Protocols
Study-Specific Publications
No study-specific publications defined.
Study-Specific Resources
No study-specific resources defined.
Prostate Rapid Reference Set Applicant: Diamandis - Mt Sinai (2006)
No abstract available.
View more about this studyBiomarker Characteristics Summary
| Notes | Sensitivity | Specificity | Prevalence | NPV | PPV | Specific Assay Type |
|---|---|---|---|---|---|---|
| Measured among 123 samples (60 controls and 63 cases). Among the cases, 33 had low Gleason grade (<7) and 30 had high Gleason grade (>=7). When comparing cases with Gleason grade >=7 (n=30) to the pool of controls and cases with Gleason grade <7 (n=93), the AUC was 0.59 (0.46, 0.71). No specific cutoff was preselected for this analysis. | 0.0 | 0.0 | 0.0 | |||
| Measured among 123 samples (60 controls and 63 cases). Among the cases, 33 had low Gleason grade (<7) and 30 had high Gleason grade (>=7). When comparing all cases (low and high Gleason grade) to controls, the AUC was 0.51 (0.41, 0.62). No specific cutoff was preselected for this analysis. | 0.0 | 0.0 | 0.0 |
Decision Rule
No clinically useful decision rule found.
Additional Study-Specific Protocols
Study-Specific Publications
No study-specific publications defined.
Study-Specific Resources
No study-specific resources defined.
Organ-Specific Protocols
No organ-specific protocols defined.
Organ-Specific Publications
No organ-specific publications defined.
Organ-Specific Resources
No organ-specific resources defined.
Studies
No associated studies or protocols found.
